Summit Therapeutics SMMT
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Summit Therapeutics (SMMT) Business Model and Operations Summary
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Key Insights
Summit Therapeutics (SMMT) Core Market Data and Business Metrics
Latest Closing Price
$18.8Market Cap
$13.94 BillionPrice-Earnings Ratio
-60.65Total Outstanding Shares
737.68 Million SharesTotal Employees
159Dividend
No dividendIPO Date
March 5, 2015SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
601 Brickell Key Drive, Miami, FL, 33131
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $381.23 Million |
| Net Cash Flow From Operating Activities | $-142.11 Million |
| Net Cash Flow From Operating Activities, Continuing | $-142.11 Million |
| Net Cash Flow, Continuing | $33.78 Million |
| Net Cash Flow From Investing Activities | $-205.34 Million |
| Net Cash Flow From Investing Activities, Continuing | $-205.34 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Parent | $-221.31 Million |
| Diluted Average Shares | $718.54 Million |
| Net Income/Loss | $-221.31 Million |
| Operating Income/Loss | $-226.00 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Diluted Earnings Per Share | $-0.31 |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-221.15 Million |
| Comprehensive Income/Loss | $-221.15 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $-221.15 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Liabilities | $46.81 Million |
| Accounts Payable | $4.64 Million |
| Equity Attributable To Parent | $388.75 Million |
| Equity Attributable To Noncontrolling Interest | $0 |
| Liabilities And Equity | $435.56 Million |
| Wages | $11.98 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||